Bladder cancer monitoring using two novel urinary markers.
Bladder cancer shows extreme variability in its behavior. Even the superficial forms, when surgically treated, are characterized by a high recurrence rate and therefore regular and intensive post-treatment monitoring is an important aspect of the management of this tumor. The standard follow-up of patients with a bladder cancer history is based on cystoscopic examination of the internal bladder, which is an invasive procedure causing discomfort to the patient. In this context, the availability of a non-invasive laboratory test which measures circulating markers associated with bladder cancer could facilitate with monitoring of patients and could be of help in understanding the metastatic potential of bladder tumors, especially the superficial forms.
Botti
C
C
Nuclear Medicine Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano.
Seregni
E
E
Mattioli
S
S
Martinetti
A
A
Ferrari
L
L
Bombardieri
E
E
D000951:Antigens, Neoplasm / Q000652:urine; D014408:Biomarkers, Tumor / Q000652:urine*; D002295:Carcinoma, Transitional Cell / Q000652:urine*; D005500:Follow-Up Studies; D006801:Humans; D007841:Latex Fixation Tests; D009363:Neoplasm Proteins / Q000652:urine*; D009687:Nuclear Proteins / Q000652:urine*; D011933:Reagent Kits, Diagnostic; D012680:Sensitivity and Specificity; D001749:Urinary Bladder Neoplasms / Q000652:urine*
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D011933:Reagent Kits, Diagnostic; C112999:bladder tumor-associated antigen; C100379:nuclear matrix protein 22